stockrowAmylyx Pharmaceuticals, Inc. (AMLX) vs Regencell Bioscience Holdings Limited (RGC)
- Amylyx Pharmaceuticals, Inc. AMLX 27.79 −5.48%
- Regencell Bioscience Holdings Limited RGC 5.16 −4.80%
Amylyx Pharmaceuticals, Inc. and Regencell Bioscience Holdings Limited are both Drug Manufacturers Specialty & Generic companies. Amylyx Pharmaceuticals, Inc. is the larger, with a market value of $3.5B against $2.6B — 1.3× the size. Across the 7 metrics below, Regencell Bioscience Holdings Limited leads on 4 and Amylyx Pharmaceuticals, Inc. on 3.
Valuation
Profitability
| Metric | AMLX | RGC | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | (42.65%) | — | 53.51% |
| Operating margin | 0.00% | — | 0.00% |
| Net margin | 0.00% | 0.00% | (2.45%) |
| Free cash flow margin | 0.00% | 0.00% | 0.00% |
| Return on equity | (74.73%) | 0.00% | (0.80%) |
| Return on assets | (66.25%) | 0.00% | (1.67%) |
| Return on invested capital | 0.00% | 0.00% | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack